Molecular Biology Enzymes, Kits & Reagents Market to Exceed USD 63.0 Billion by 2034, with a CAGR of 13.7% and Pioneering Precision Medicine Solutions - By PMI
February 28, 2024 17:25 ET
|
PMI
Covina, Feb. 28, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Molecular Biology Enzymes, Kits & Reagents Market size was valued at about USD 17.5 Billion in 2024 and...
Active Pharmaceutical Ingredients Market To Reach USD 346.4 Billion By 2032 at CAGR 8.7%| DataHorizzon Research
January 15, 2024 07:30 ET
|
DataHorizzon Research
Colorado, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The Active Pharmaceutical Ingredients (API) Market size was valued at USD 151.2 Billion in 2022 and is expected to reach USD 346.4 Billion by 2032 at a...
Pharmaceutical Industry Continues to Fuel Growth of Cell-Based Assay Market – By PMI
November 01, 2023 14:30 ET
|
PMI
Covina, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Introduction – Cell-based assays can measure a wide range of cellular activities, including cell viability, proliferation, apoptosis, and the function of...
IRBM Extends Peptide Therapeutics Collaboration with Merck & Co. Inc., Rahway NJ USA
June 22, 2023 16:30 ET
|
IRBM
ROME, June 22, 2023 (GLOBE NEWSWIRE) -- IRBM, an innovative contract research organization, today announced it has signed a new agreement with Merck & Co. Inc., Rahway NJ USA, known as MSD...
Pediatric Vaccines Market is Expected to Reach $36.4 Billion by 2031: Says AMR
November 18, 2022 07:32 ET
|
Allied Market Research
Portland, OR, Nov. 18, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Pediatric Vaccines Market was estimated at $21.4 billion in 2021 and...
Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer
April 08, 2021 08:00 ET
|
Immutep Limited
Fast Track designation opens the potential for expedited development and review with the US FDAFast Track was granted based on the promising data package from Immutep, including from Immutep’s Phase...
Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer
March 16, 2021 08:00 ET
|
Immutep Limited
New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)HNSCC is one of the...
Global Diabetes Drugs Market–Analysis and Demand with Forecast Overview to 2029 - by PMI
January 12, 2021 10:05 ET
|
PMI
Covina, CA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs...